Providing educated insights on nephrology pharmaceutical and biotech companies
Latest from the Blog
AKBA has lost 70%+ of it’s value from a 52-week high and closed today at $2.40. As of this writing, the stock hemorrhaged 40% of its value since Friday over a three-day trading period. On Friday, I warned of the impending loss on social media. Upon confirmation of my outlook, I started this blog to … Continue reading Akebia (AKBA) Outlook
Get new content delivered directly to your inbox.